Barbiturate-refractory epilepsy: safe schedule for therapeutic substitution.

Area of Science:

• Neurology
• Pharmacology

Background:

• Barbiturates are commonly used as first-line antiepileptic drugs (AEDs) in developing countries due to cost and tradition.
• However, their long-term efficacy and potential for treatment resistance are significant concerns.

Purpose of the Study:

• To investigate the characteristics of patients who develop refractory epilepsy while on barbiturates.
• To establish a safe and effective protocol for barbiturate withdrawal and transition to alternative AEDs.

Main Methods:

• A prospective, uncontrolled study involving 52 patients (aged 15-64 years) with epilepsy treated with barbiturates.
• Patients refractory to barbiturates underwent a gradual withdrawal over 2-8 months, with concurrent initiation of carbamazepine, phenytoin, or sodium valproate.

Main Results:

• Refractory epilepsy was primarily associated with partial seizures (with or without generalization) or focal EEG abnormalities (71% of cases).
• Seizure refractoriness typically emerged around 6 years after initiating barbiturate therapy.
• Complete barbiturate withdrawal was achieved in 81% of patients (42/52).
• Following withdrawal, monthly seizure frequency decreased significantly from 7.1 to 1.7 per patient.

Conclusions:

• Barbiturates may not be optimal first-choice AEDs for chronic epilepsy management.
• A structured barbiturate withdrawal schedule, without requiring hospitalization or serum drug monitoring, is safe and effective.
• This approach facilitates transition to alternative AEDs and improves seizure control.